Re­gen­eron teams with gene ther­a­py pi­o­neer James Wil­son, adapt­ing its Covid-19 an­ti­body cock­tail to an AAV-based nasal spray

Gene ther­a­py pi­o­neer James Wil­son is ap­ply­ing his knowl­edge and ex­pe­ri­ence in the field to a new fron­tier: the Covid-19 pan­dem­ic.

Wil­son and his col­leagues at the Uni­ver­si­ty of Penn­syl­va­nia have signed a col­lab­o­ra­tion agree­ment with an­ti­body star Re­gen­eron $REGN to com­bine the biotech’s Covid-19 an­ti­body cock­tail with a nasal spray-based AAV de­liv­ery plat­form. The re­search could hit the clin­ic ear­ly next year, with the pair aim­ing to ap­ply for an IND af­ter val­i­dat­ing the an­ti­bod­ies’ ef­fec­tive­ness in an an­i­mal mod­el chal­lenge study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.